JP2023507799A5 - - Google Patents
Info
- Publication number
- JP2023507799A5 JP2023507799A5 JP2022538229A JP2022538229A JP2023507799A5 JP 2023507799 A5 JP2023507799 A5 JP 2023507799A5 JP 2022538229 A JP2022538229 A JP 2022538229A JP 2022538229 A JP2022538229 A JP 2022538229A JP 2023507799 A5 JP2023507799 A5 JP 2023507799A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- product according
- pharmaceutical product
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952042P | 2019-12-20 | 2019-12-20 | |
| US62/952,042 | 2019-12-20 | ||
| US202063009754P | 2020-04-14 | 2020-04-14 | |
| US63/009,754 | 2020-04-14 | ||
| PCT/US2020/065411 WO2021127046A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507799A JP2023507799A (ja) | 2023-02-27 |
| JP2023507799A5 true JP2023507799A5 (cg-RX-API-DMAC7.html) | 2023-12-25 |
Family
ID=76478099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538229A Pending JP2023507799A (ja) | 2019-12-20 | 2020-12-16 | 組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230042653A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069224A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023507799A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220119428A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115103673A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020408698A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012286A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165477A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294084A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007624A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202135810A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021127046A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5411847B2 (ja) * | 2007-04-25 | 2014-02-12 | Msd株式会社 | Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| CA2706946A1 (en) * | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| HRP20140821T1 (hr) * | 2009-09-15 | 2014-10-10 | Merck Sharp & Dohme Corp. | Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona |
| SMT201700595T1 (it) * | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
| AU2016344040B2 (en) * | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| US11932650B2 (en) * | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| EP3712150B1 (en) * | 2017-11-01 | 2024-06-12 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Macrocyclic compound serving as wee1 inhibitor and applications thereof |
| JP2022543832A (ja) * | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 変異体を治療するためのエストロゲン受容体調節剤 |
-
2020
- 2020-12-16 EP EP20901854.8A patent/EP4069224A4/en active Pending
- 2020-12-16 AU AU2020408698A patent/AU2020408698A1/en not_active Abandoned
- 2020-12-16 US US17/757,511 patent/US20230042653A1/en not_active Abandoned
- 2020-12-16 WO PCT/US2020/065411 patent/WO2021127046A1/en not_active Ceased
- 2020-12-16 CN CN202080095319.0A patent/CN115103673A/zh active Pending
- 2020-12-16 KR KR1020227024839A patent/KR20220119428A/ko not_active Ceased
- 2020-12-16 MX MX2022007624A patent/MX2022007624A/es unknown
- 2020-12-16 BR BR112022012286A patent/BR112022012286A2/pt not_active IP Right Cessation
- 2020-12-16 IL IL294084A patent/IL294084A/en unknown
- 2020-12-16 CA CA3165477A patent/CA3165477A1/en active Pending
- 2020-12-16 JP JP2022538229A patent/JP2023507799A/ja active Pending
- 2020-12-18 TW TW109145166A patent/TW202135810A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508325A5 (cg-RX-API-DMAC7.html) | ||
| Šarenac et al. | Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease | |
| JP2023507797A5 (cg-RX-API-DMAC7.html) | ||
| Richie et al. | Breast cancer: a review of the literature | |
| Verschraegen et al. | Clinicopathologic analysis of mullerian adenosarcoma: the MD Anderson Cancer Center experience. | |
| JP5363310B2 (ja) | 乳癌及び関連疾患に対する薬剤 | |
| Beckmann et al. | Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates | |
| Pontrelli et al. | Primary vaginal adenosarcoma with sarcomatous overgrowth arising in recurrent endometriosis: feasibility of laparoscopic treatment and review of the literature | |
| Malik et al. | Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach? | |
| Yousefnia | Breast cancer, subtypes, risk factors, and treatment | |
| CN100408036C (zh) | 阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途 | |
| Soh et al. | Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women | |
| Fan et al. | Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer | |
| Goodman | Primary vaginal cancer | |
| Erkanli et al. | Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy | |
| Ahmad et al. | Frequency of primary solid malignant neoplasms in both sexes, as seen in our practice | |
| Yu | 17β‐Estradiol epoxidation as the molecular basis for breast cancer initiation and prevention | |
| Lentini et al. | Computed tomography in retroconversion of hepatic metastases from immature ovarian teratoma | |
| Cetin et al. | Squamous cell carcinoma of the vagina | |
| Rodrigues-Fernandes et al. | Oral epithelioid rhabdomyosarcoma: report of a rare case and literature review of a distinct variant of rhabdomyosarcoma | |
| Benjamin et al. | First report of primary fallopian tube cancer diagnosed by liquid-based cytology in an asymptomatic woman. | |
| van der Veldt et al. | Metastatic renal cell cancer in a 20-year-old pregnant woman | |
| Zin et al. | Primary Vaginal Melanoma–Cytohistological Correlates and Literature Reviews | |
| Chakalova et al. | Endometrial carcinoma in a 20 years old or less female: a rare presentation of four cases | |
| Arslan et al. | Case Report Isolated Uterine Metastasis of Invasive Ductal Carcinoma |